Global Ganja Report

With passage of the Farm Bill and removal of hemp-derived CBD from controlled substance status, big market growth is expected for the very chic and purportedly salubrious non-psychoactive cannabinoid. The law is a win for a nascent CBD industry that has been struggling to shake off the lingering stigma surrounding (psychoactive) cannabis. The effort to segment cannabidiol from "marijuana" is exemplified in the several states that now have "CBD-only" laws.

2018 saw historic strides toward the liberation of the cannabis plant, from the proverbial four corners of the Earth—North America to the Antipodes. Canadian legalization garnered big headlines, but there were significant breaks with the global prohibition regime in several other countries—including some seemingly unlikely candidates, in regions where the anti-cannabis stigma is deeply entrenched.

From the "Tulip Mania" in 15th century Holland to the Bitcoin bubble of 2017, high hopes for a commodity's market performance can lead to unsustainable overvaluation inevitably followed by a painful correction. Many observers believe that cannabis fell prey to this phenomenon in 2018—but are hoping for growth in a more rational and realistic market in the coming year.

It has long been established that cannabis can effectively treat glaucoma, a condition that damages the optic nerve and can lead to blindness. However, new research indicates that while THC helps fight glaucoma, its cousin cannabinoid CBD has the opposite effect—and could actually counteract the efficacy of THC.

In his new memoir True Stories: Tales from the Generation of a New World Culture, Garrick Beck spans a personal journey through radical bohemia in the 1950s, hippie utopianism in the 1960s, back-to-the-land communalism in the 1970s, to applying those ethics today through community work and urban land-reclamation back in the New York City of his youth.

He was born into artistic activism as the offspring of Julian Beck and Judith Malina, the leading figures of the Living Theatre.

The newly enacted Farm Bill contains language implicitly removing hemp-derived CBD from the controlled substances list, along with industrial hemp. A CBD industry that has been growing fast in a legal grey zone stands to grow faster in the light of legal clarity. Conflicting state laws and even federal regulations, however, could prove an obstacle to unfettered expansion.

When the United Kingdom announced the historic step of rescheduling cannabis and allowing physicians to prescribe it two months ago, there was concern from patients and advocates as to whether actual herbaceous flower would be allowed, or only extracts. Now the first patient is approved to receive cannabis under the program, and it is indeed to be dried flower. The bad news: with the National Health Service barred by bureaucratic hurdles from providing it, patients are at the mercy of the market—and the price is prohibitive. 

Terpenes, the chemical compounds that give your herb its distinctive smell and flavor, are increasingly recognized as a vital part of the overall cannabis experience. But with the growing popularity of vape pens and concentrates, industry is now adding terpenes to products in an effort to recreate that whole-flower feel. These may come from plants other than cannabis—and some may even be synthetic.